These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 36244992)

  • 1. Rare lysosomal disease registries: lessons learned over three decades of real-world evidence.
    Mistry PK; Kishnani P; Wanner C; Dong D; Bender J; Batista JL; Foster J
    Orphanet J Rare Dis; 2022 Oct; 17(1):362. PubMed ID: 36244992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rare partnership: patient community and industry collaboration to shape the impact of real-world evidence on the rare disease ecosystem.
    Klein TL; Bender J; Bolton S; Collin-Histed T; Daher A; De Baere L; Dong D; Hopkin J; Johnson J; Lai T; Pavlou M; Schaller T; Žnidar I
    Orphanet J Rare Dis; 2024 Jul; 19(1):262. PubMed ID: 38987844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transformative effect of a Humanitarian Program for individuals affected by rare diseases: building support systems and creating local expertise.
    Verma IC; El-Beshlawy A; Tylki-Szymańska A; Martins A; Duan YL; Collin-Histed T; van der Linde MS; Mansour R; Dũng VC; Mistry PK
    Orphanet J Rare Dis; 2022 Apr; 17(1):87. PubMed ID: 35369888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.
    Wyatt K; Henley W; Anderson L; Anderson R; Nikolaou V; Stein K; Klinger L; Hughes D; Waldek S; Lachmann R; Mehta A; Vellodi A; Logan S
    Health Technol Assess; 2012; 16(39):1-543. PubMed ID: 23089251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating lysosomal storage disorders: What have we learnt?
    Lachmann RH
    J Inherit Metab Dis; 2020 Jan; 43(1):125-132. PubMed ID: 31140601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients' view on gene therapy development for lysosomal storage disorders: a qualitative study.
    Eskes ECB; Beishuizen CRL; Corazolla EM; van Middelaar T; Brands MMMG; Dekker H; van de Mheen E; Langeveld M; Hollak CEM; Sjouke B
    Orphanet J Rare Dis; 2022 Oct; 17(1):383. PubMed ID: 36271424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A charitable access program for patients with lysosomal storage disorders in underserved communities worldwide.
    Mehta A; Ramaswami U; Muenzer J; Giugliani R; Ullrich K; Collin-Histed T; Panahloo Z; Wellhoefer H; Frader J
    Orphanet J Rare Dis; 2021 Jan; 16(1):8. PubMed ID: 33407729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement therapy for lysosomal storage diseases.
    Ohashi T
    Pediatr Endocrinol Rev; 2012 Oct; 10 Suppl 1():26-34. PubMed ID: 23330243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The NCS-LSD cohort study: a description of the methods and analyses used to assess the long-term effectiveness of enzyme replacement therapy and substrate reduction therapy in patients with lysosomal storage disorders.
    Henley WE; Anderson LJ; Wyatt KM; Nikolaou V; Anderson R; Logan S
    J Inherit Metab Dis; 2014 Nov; 37(6):939-44. PubMed ID: 24519353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: A nationwide survey in Japan.
    Koto Y; Sakai N; Lee Y; Kakee N; Matsuda J; Tsuboi K; Shimozawa N; Okuyama T; Nakamura K; Narita A; Kobayashi H; Uehara R; Nakamura Y; Kato K; Eto Y
    Mol Genet Metab; 2021 Jul; 133(3):277-288. PubMed ID: 34090759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac involvement in Lysosomal Storage Diseases.
    Sestito S; Parisi F; Tallarico V; Tarsitano F; Roppa K; Pensabene L; Chimenz R; Ceravolo G; Calabrò MP; De Sarro R; Moricca MT; Bonapace G; Concolino D
    J Biol Regul Homeost Agents; 2020; 34(4 Suppl. 2):107-119. SPECIAL ISSUE: FOCUS ON PEDIATRIC CARDIOLOGY. PubMed ID: 33000609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of rare disease registries in latin america.
    Martins AM; Kerstenezky M; Linares A; Politei J; Kohan R; Ospina S; Varas C; Villalobos J; Amartino H; Franco S; Valadez G; Giugliani R; Guerra P; Sanches L
    JIMD Rep; 2011; 1():111-5. PubMed ID: 23430837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders.
    Hollak CE; Aerts JM; Aymé S; Manuel J
    Orphanet J Rare Dis; 2011 Apr; 6():16. PubMed ID: 21496291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world patient data on immunity and COVID-19 status of patients with MPS, Gaucher, and Pompe diseases from Turkey.
    Kilavuz S; Kor D; Bulut FD; Serbes M; Karagoz D; Altıntas DU; Bisgin A; Seydaoğlu G; Mungan HNO
    Arch Pediatr; 2022 Aug; 29(6):415-423. PubMed ID: 35705384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease.
    Abasolo I; Seras-Franzoso J; Moltó-Abad M; Díaz-Riascos V; Corchero JL; Pintos-Morell G; Schwartz S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 May; 13(3):e1684. PubMed ID: 33314628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: A Review of the Evidence and Informed Approach to Reclassification.
    Keyzor I; Shohet S; Castelli J; Sitaraman S; Veleva-Rotse B; Weimer JM; Fox B; Willer T; Tuske S; Crathorne L; Belzar KJ
    Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy.
    Burlina AB; Polo G; Salviati L; Duro G; Zizzo C; Dardis A; Bembi B; Cazzorla C; Rubert L; Zordan R; Desnick RJ; Burlina AP
    J Inherit Metab Dis; 2018 Mar; 41(2):209-219. PubMed ID: 29143201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri.
    Hopkins PV; Campbell C; Klug T; Rogers S; Raburn-Miller J; Kiesling J
    J Pediatr; 2015 Jan; 166(1):172-7. PubMed ID: 25444528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of lysosomal storage diseases: recent patents and future strategies.
    Ortolano S; Viéitez I; Navarro C; Spuch C
    Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):9-25. PubMed ID: 24433521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurological manifestations in lysosomal storage disorders - from pathology to first therapeutic possibilities.
    Hoffmann B; Mayatepek E
    Neuropediatrics; 2005 Oct; 36(5):285-9. PubMed ID: 16217702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.